H2020Индивидуална стипендия2016–2018

CAP-CANCER · Cold atmospheric plasma treatment for effective cancer cell apoptosis

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2016-09-01 → 2018-08-31
Финансиране от ЕС
163 649 €
Участници
1
Схема
MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Студената атмосферна плазма се изследва като метод за унищожаване на ракови клетки, без да се уврежда здравата тъкан около тях. Разбирането на този процес може да намали болката и времето за възстановяване на пациентите след хирургични операции.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Cold atmospheric plasma treatment for effective cancer cell apoptosis

Some of the most useful tools at the hands of a surgeon operating on a cancer patient are energy sources such as Lasers, monopolar and bipolar electrocautery. Those tools deliver heat (they increase the temperature) to the targeted (usually diseased tissue such as cancerous etc.) tissue, cutting it, coagulating (burning and stopping the blood flow) and ablating it (evaporating it). Despite their wide use, there are two major challenges with thermal energy tools, namely non-selectivity and collateral damage. Collateral damage translates into longer recovery time and pain, and into the possibility of serious injury to critical tissue and in some cases abandonment of treatment. It will therefore be highly desirable to have a surgical energy source that does not cause collateral thermal damage and can selectively treat the cancerous tissue without affecting the healthy one. Such a source would have significant implications in the surgical treatment of cancer. It would result in less pain and faster recovery times for the patient and in the ability to cure forms of inoperable cancer. This project deals with a new type of energy known as cold atmospheric plasma (CAP) which has shown promising results exhibiting almost no thermal collateral damage and also selectivity in treatment. CAP is inexpensive, easy to work with and opens up the possibilities of biomedical applications. Because CAP is non-thermal, the absence of collateral thermal damage is well understood and intuitive. The selectivity aspect of CAP though, is not well understood and this is the focus of this proposed research. The overall objective of the project is to aid in the understanding of the phenomenon of the selectivity of CAP. It achieves that by developing numerical models that help understand the complex mechanisms of CAP with tissue and by conducting biological experiments where cancerous and non-cancerous cells are treated with CAP. This work showed that CAP could be understood as interacting with tissue in two ways that are interconnected. The first being an electric field and the second being a slew of reactive oxygen and nitrogen species (RS) such as NO, OH, O, H2O2 etc. The electric field causes the cells to open up (through a phenomenon known as electroporation) and that allows the RS to enter into the cells. Once a sufficient number of RS enter, the cell undergoes apoptosis (controlled and slow death). The work of CAP-CANCER showed that it is possible to adjust the plasma parameters to increase the effects electroporation and therefore apoptosis for cancerous cells. Furthermore, it also showed that cancerous cells are more susceptible to electroporation than healthy cells and this could account for the selectivity of the treatment.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Cold atmospheric plasma (CAP) has shown promise in minimally invasive surgery by selectively treating cancerous cells with little or no damage to healthy cells. The selective destruction of cancerous cells can be used to aid and enhance current cancer treatments and can also be the cure for forms of inoperable cancer. The selective treatment can be obtained by using the plasma to induce cell apoptosis, in which the cell self-destructs in a tightly controlled way without causing inflammation in the surrounding tissue. One of the major challenges of this research is that the exact mechanism of plasma induced apoptosis is not well understood. The fellow proposes to test the hypothesis CAP builds up electric fields across the cell membrane that cause electroporation for the cancerous but not the healthy cell because they have different electrical and physical properties. Electroporation allows for the penetration of reactive oxygen species (ROS) into the cancerous cell causing apoptosis while leaving the healthy cells intact. The fellow will develop numerical simulations to allow the study of cell surface electric fields and generation of ROS will explore the parameter space in which the electroporation and therefore apoptosis will be induced only for the cancerous cells. During his secondment the Fellow will perform experiments by applying CAP onto two Breast cell lines: MDA-MB-231 (cancerous) MCF-12F (healthy) and will use flow cytometry to measure electroporation and apoptosis. The results of this research will elucidate how CAP interacts with tissue and under what conditions it causes apoptosis. This will allow us to get closer to an actual medical device utilizing CAP to treat cancer on patients. The fellow will gain scientific skills in cell culture handling, storing, preparation, plasma sources and characterization and complementary skills and will reach a position of professional maturity and leadership in research and development in Europe.

Оригинален текст от CORDIS (на английски).

Участници

  • UNIVERSITY OF CYPRUS · NicosiaКоординаторКипър

Връзки

Данни: CORDIS, © Европейски съюз